Danting Zhu
Overview
Explore the profile of Danting Zhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
102
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wollenberg A, Ikeda M, Chu C, Eichenfield L, Seyger M, Prakash A, et al.
J Dermatolog Treat
. 2024 Nov;
35(1):2411834.
PMID: 39522957
Background: Baricitinib, an oral selective Janus kinase inhibitor, improved clinical signs and symptoms of moderate-to-severe atopic dermatitis (AD) at week 16 in the phase 3 pediatric study BREEZE-AD-PEDS. Objective: To...
2.
De Vlam K, Maksymowych W, Gallo G, Rahman P, Mease P, Krishnan V, et al.
Rheumatol Ther
. 2024 Jun;
11(4):1063.
PMID: 38874859
No abstract available.
3.
Ly L, Zhu D, Schaubel D, Woodside K, Sung R
Clin Transplant
. 2024 Apr;
38(5):e15319.
PMID: 38683684
Objective: Longer end-stage renal disease time has been associated with inferior kidney transplant outcomes. However, the contribution of transplant evaluation is uncertain. We explored the relationship between time from evaluation...
4.
De Vlam K, Maksymowych W, Gallo G, Rahman P, Mease P, Krishnan V, et al.
Rheumatol Ther
. 2024 Apr;
11(3):691-707.
PMID: 38637464
Introduction: The objective of this analysis is to evaluate the improvement in spinal pain with ixekizumab, placebo, and adalimumab based on objective measures of inflammation response in patients with ankylosing...
5.
Deodhar A, Blauvelt A, Lebwohl M, Feely M, Kronbergs A, Eberhart N, et al.
Arthritis Res Ther
. 2024 Feb;
26(1):49.
PMID: 38347650
Background: We report long-term, end-of-study program safety outcomes from 25 randomized clinical trials (RCTs) in adult patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) [including ankylosing spondylitis...
6.
Wen W, Guo C, Chen Z, Yang D, Zhu D, Jing Q, et al.
PLoS One
. 2023 Nov;
18(11):e0294700.
PMID: 38032938
Alcoholic myopathy is caused by chronic consumption of alcohol (ethanol) and is characterized by weakness and atrophy of skeletal muscle. Regular exercise is one of the important ways to prevent...
7.
Feng L, Zhou J, Zhu D, Gao C
Trends Plant Sci
. 2023 Nov;
29(3):383-384.
PMID: 37949706
No abstract available.
8.
Torrelo A, Rewerska B, Galimberti M, Paller A, Yang C, Prakash A, et al.
Br J Dermatol
. 2023 Mar;
189(1):23-32.
PMID: 36999560
Background: Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, is approved in many countries for moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. Objectives: To evaluate...
9.
Wu X, Zhu D, Shi L, Tu Q, Yu Y, Chen J
Heliyon
. 2023 Mar;
9(3):e13975.
PMID: 36873496
Objectives: To investigate the role of AdipoRon in bone wound healing of calvaria critical-sized defects (CSD) in diet-induced obesity (DIO) mice. Materials And Methods: After establishing the calvaria CSD in...
10.
Griffiths C, Gooderham M, Colombel J, Terui T, Accioly A, Gallo G, et al.
Dermatol Ther (Heidelb)
. 2022 May;
12(6):1431-1446.
PMID: 35624407
Introduction: We report a comprehensive summary of the safety outcomes in adult patients with moderate-to-severe psoriasis with up to 5 years of exposure to ixekizumab. Methods: Long-term safety of the...